Radiopharmaceuticals Hit Safety Snags in Trials
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Radiopharmaceuticals have been marketed as a precision alternative to traditional beam radiation, designed to deliver chemical-warfare-style targeting directly to tumors while sparing healthy tissue.
- The drug industry has embraced radiopharmaceuticals as a new field of drug development, with growing investment driving more therapies into clinical trials.
- Radiopharmaceutical developers are discovering safety issues as clinical trials expand: some isotopes, while hurtling toward their biological targets, are inadvertently zapping patients' kidneys, liver, or bone marrow.
- The isotopes underlying radiopharmaceuticals are described as just as virulent as the beam radiation patients have tolerated for decades, undermining the targeted-delivery pitch.
- Cancer treatment developers are finding the reality of radiopharmaceuticals is 'not so clear-cut' compared to the elegant central promise of tumor-only radiation delivery.
Why it matters: The gap between radiopharmaceuticals' elegant pitch — tumor-only radiation — and the clinical reality of collateral organ damage in kidneys, liver, and bone marrow threatens to slow one of the drug industry's hottest new development fields just as investment and trial activity accelerate.
Ask SkimNews
